Hematology, Transfusion and Cell Therapy最新文献

{"title":"18F-PSMA PET/CT IN THE MULTIMODAL ASSESSMENT OF METASTATIC GASTRIC ADENOCARCINOMA: A CASE REPORT","authors":"Renata Erbert Contriciani,&nbsp;Fabíola Furtuoso Zarpelão,&nbsp;Larissa Ariel Oliveira Carrilho,&nbsp;Barbara Cipriano,&nbsp;Leo Victor Kim,&nbsp;Sandra Regina Branbilla,&nbsp;Caroline Torricelli Corrêa,&nbsp;Natália Tobar Toledo Prudente da Silva,&nbsp;Luiz Roberto Lopes,&nbsp;Nelson Adami Andreollo,&nbsp;Maria Carolina Santos Mendes,&nbsp;Elba C.S.C. Etchebehere,&nbsp;José Barreto Campello Carvalheira","doi":"10.1016/j.htct.2026.106343","DOIUrl":"10.1016/j.htct.2026.106343","url":null,"abstract":"<div><h3>Introduction</h3><div>The expression of Prostate Specific Membrane Antigen (PSMA) in the neovascular endothelium of non-prostatic tumors has presented new diagnostic perspectives. This report describes a young female patient with metastasis from gastric adenocarcinoma who underwent 18F-PSMA PET/CT during staging.</div></div><div><h3>Case Report</h3><div>A 42-year-old female with no prior oncologic history was diagnosed with metastatic gastric adenocarcinoma (cT4bN3M1). As part of an institutional clinical trial, she underwent 18F-FDG and 18F-PSMA PET/CT before treatment initiation. Imaging revealed central nervous system (CNS) involvement, non-regional lymphadenopathy, bone metastasis and muscle implants. In the primary tumor, 18F-FDG uptake was higher than 18F-PSMA (SUVmax 23.5 vs. 6.4). A 1.5 cm brain metastasis in the left frontal lobe showed substantial uptake in both studies (SUV max 9.1 for PSMA vs. 15.4 for FDG). Notably, 18F-PSMA exclusively identified additional focal areas in the right frontal and temporal lobes (SUV max 9.2), further imaging studies are pending. Additionally, a T6 vertebral lesion (SUVmax 4.8) was present in the PSMA study and was occult on 18F-FDG PET/CT. The patient was referred for CNS radiotherapy and initiated palliative chemotherapy with capecitabine and oxaliplatin.</div></div><div><h3>Discussion</h3><div>The clinical utility of PSMA PET/CT in gastric cancer remains poorly explored in the literature. In this case, PSMA PET/CT demonstrated significant uptake in CNS and bone lesions, suggesting sensitivity for detecting specific metastatic sites through tumor neovasculature imaging.</div></div><div><h3>Conclusion</h3><div>18F-PSMA PET/CT represents a promising diagnostic tool in non-prostate malignancies and may provide incremental diagnostic value when used in conjunction with 18F-FDG PET/CT. Further clinical trials investigating the role of PSMA-targeting tracers in gastrointestinal cancers are warranted.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 ","pages":"Article 106343"},"PeriodicalIF":1.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147452161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NANOENCAPSULATION OF THE GOLD(I) COMPLEX AUMTZ IN LIPID CARRIERS IMPROVES SELECTIVITY AND ANTITUMOR ACTIVITY IN CUTANEOUS SQUAMOUS CELL CARCINOMA MODELS","authors":"Fernanda Van Petten Vasconcelos Azevedo,&nbsp;Gabriela Geronimo,&nbsp;Camilla Abbehausen,&nbsp;Eneida de Paula,&nbsp;Carolina Coli Zuliani,&nbsp;Carmen Silvia Passos Lima","doi":"10.1016/j.htct.2026.106291","DOIUrl":"10.1016/j.htct.2026.106291","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Cutaneous squamous cell carcinoma (cSCC) is a non-melanoma skin cancer and can be difficult to manage in locally advanced or recurrent disease, where wide excision may compromise function and aesthetics and systemic regimens are constrained by toxicity and limited selectivity. Gold(I) metallodrugs such as AuMTZ are attractive candidates because redox disruption can promote oxidative stress and regulated cell death in tumor cells; however, poor dispersion and chemical instability may limit translation. Nanostructured lipid carriers (NLCs) can protect labile compounds, modulate exposure, and support topical-oriented development. This study evaluated AuMTZ and tested whether nanoencapsulation (AuNLC) improves the antitumor/selectivity profile in cSCC-related models.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Methods&lt;/h3&gt;&lt;div&gt;AuMTZ was synthesized and characterized following original chemical standards, and the nanoencapsulated formulation was denominated AuNLC. AuNLC was physicochemically characterized and shelf stability was monitored for 270 days. Antitumor response was assessed in FaDu, SCC-4, SCC-9, SCC-25 and non-tumoral keratinocytes (HaCaT). MTT (viability) and SRB (antiproliferative) dose–response assays were performed from 0.39–100 µM. Intracellular ROS (DCFDA), apoptosis by flow cytometry (Annexin V/7-AAD), migration (wound healing), invasion (Transwell-Matrigel), and 3D validation in spheroids generated in molds (n=260) by Live/Dead microscopy and morphometry.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;AuNLC showed long-term physicochemical stability over 270 days (size ∼215–300 nm; PDI ∼0.16–0.30; zeta potential ∼ -29 to -13 mV), with no macroscopic aggregation. In MTT (0.39–100 µM), tumor lines showed concentration-dependent reductions, while HaCaT remained the most resistant within the same range. In SRB (TGI = 0% growth), both gold-based conditions were highly active in sensitive models: FaDu (AuMTZ =0.781 µM; AuNLC =0.781 µM) and SCC-9 (AuMTZ =0.781 µM; AuNLC =0.781 µM). In SCC-25, thresholds differed (AuMTZ =1.562 µM; AuNLC =12.5 µM), indicating cell line–dependent formulation impact. In HaCaT, both remained TGI &gt;100 µM, supporting a favorable selectivity window. At fixed doses (3 and 25 µM), ROS increased (DCFDA) and flow cytometry confirmed apoptotic progression, with late apoptosis ranging 35–59% at 3 µM across the evaluated lines. Migration and invasion were reduced at both concentrations, with inhibition observed independent of matrix context. In 3D validation (n = 260), Live/Dead imaging showed treatment-dependent reductions in viability in tumor-derived spheroids, more pronounced under AuNLC, while HaCaT spheroids maintained high viability; global morphology remained preserved (solidity ∼1; Feret diameters: FaDu 425±39 µm, SCC-4 663±38 µm, SCC-9 678±33 µm, SCC-25 515±39 µm, HaCaT 609±27 µm).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;AuMTZ displays strong antitumor activity in SCC models, and NLC nanoencapsula","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 ","pages":"Article 106291"},"PeriodicalIF":1.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147452164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PROGNOSTIC IMPACT OF GLIM-DEFINED MALNUTRITION IN PATIENTS WITH RESECTABLE GASTRIC CANCER","authors":"Ananda Giovana Cabral Silva,&nbsp;Sandra Regina Branbilla,&nbsp;Ligia M. Antunes Correa,&nbsp;José Barreto Campello Carvalheira,&nbsp;Maria Carolina Santos Mendes","doi":"10.1016/j.htct.2026.106328","DOIUrl":"10.1016/j.htct.2026.106328","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Gastric cancer remains among the leading causes of cancer-related mortality worldwide. Malnutrition is highly prevalent in oncology patients and is associated with poorer clinical and prognostic outcomes. The Global Leadership Initiative on Malnutrition (GLIM) proposes standardized criteria for the diagnosis of malnutrition, integrating phenotypic and etiologic parameters and allowing a comprehensive assessment of nutritional status. However, the prognostic impact of GLIM-defined malnutrition in patients with resectable gastric cancer remains insufficiently explored.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To evaluate the prevalence of malnutrition according to GLIM criteria and its association with body composition and overall survival in patients with resectable gastric cancer.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This retrospective study included patients with gastric cancer who underwent surgical treatment at the Hospital de Clínicas of the University of Campinas (UNICAMP) between 2010 and 2018 and was approved by the Institutional Research Ethics Committee (CAAE: 90784618.1.0000.5404). Demographic and clinical data were collected, along with computed tomography images for body composition assessment. Malnutrition was diagnosed according to GLIM criteria, considering both phenotypic and etiologic components, with systemic inflammation assessed by the neutrophil-to-lymphocyte ratio (NLR). The primary outcome was overall survival.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 272 patients were included, with a median age of 62 years (IQR: 55–69) and a predominance of males (68%). Malnutrition according to GLIM criteria was identified in 69% of patients at the time of cancer diagnosis. Among phenotypic criteria, 72% presented weight loss, 28% low body mass index, and 26% low muscularity. Regarding etiologic criteria, 65% had reduced food intake and 43% showed systemic inflammation assessed by NLR. Malnourished patients had lower skeletal muscle area (129 vs. 142 cm²; p &lt; 0.001) and skeletal muscle index (48.1 vs. 53.2 cm²/m²; p &lt; 0.001), as well as a higher prevalence of low muscularity (31% vs. 15%; p = 0.006). Myosteatosis was observed in 66% of the sample, with no significant difference between groups. Visceral obesity was more prevalent among non-malnourished patients (46% vs. 26%; p &lt; 0.001), whereas malnourished patients showed lower visceral and subcutaneous fat areas and indices (p &lt; 0.05). In overall survival analysis, malnourished patients had a worse prognosis (HR = 2.61; 95% CI: 1.69–4.04; p &lt; 0.001). A progressive reduction in survival was observed according to malnutrition severity, with increased mortality risk in patients with moderate malnutrition (HR = 2.12; 95% CI: 1.19–3.79; p = 0.01) and severe malnutrition (HR = 2.81; 95% CI: 1.80–4.39; p &lt; 0.001). In multivariate analysis, malnutrition remained independently associated with a higher risk of mortality (HR = 1.77; 95% CI: 1.0","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 ","pages":"Article 106328"},"PeriodicalIF":1.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147452336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GROUP 10 THIOSEMICARBAZONE METAL COMPLEXES AS AN ANTIPROLIFERATIVE PLATFORM FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA","authors":"Victor Maia Miranda ,&nbsp;Fernanda Van Petten Vasconcelos Azevedo ,&nbsp;Joaldo Garcia Arruda ,&nbsp;Hirya Costa Schibelsky ,&nbsp;Daniele Daiane Affonso ,&nbsp;Carmen Silvia Passos Lima ,&nbsp;Victor Marcelo Deflon","doi":"10.1016/j.htct.2026.106300","DOIUrl":"10.1016/j.htct.2026.106300","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Head and neck squamous cell carcinomas (HNSCC) remain associated with a high clinical burden and limited therapeutic options in advanced and recurrent disease, largely due to toxicity and resistance to conventional chemotherapy. In this context, metallopharmaceuticals with tunable coordination chemistry may offer a strategy to improve antitumor potency and tumor selectivity. Square-planar Group 10 complexes of nickel(II), palladium(II), and platinum(II) coordinated to thiosemicarbazones provide a chemically controlled platform to investigate metal-dependent antiproliferative responses in HNSCC models.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;To synthesize and characterize a series of Group 10 thiosemicarbazone metal complexes and evaluate their antiproliferative activity and tumor selectivity in HNSCC cellular models.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Methods&lt;/h3&gt;&lt;div&gt;The thiosemicarbazone ligand H2bmt was synthesized and used to prepare square-planar complexes of the type [M(bmt)(PPh3)] (M = NiII, PdII, and PtII), along with chemical controls (free ligand, PPh3, and metal precursors). Compounds were characterized by FTIR, HRMS, and multinuclear NMR (¹H/¹³C/³¹P), including solution-stability assessment. Antiproliferative activity was investigated in SCC-25 and SCC-9 (tongue squamous cell carcinoma) and FaDu (hypopharyngeal squamous cell carcinoma), using HaCaT keratinocytes as a non-tumoral model. MTT assays were performed using serial dilutions across the micromolar range. In parallel, SRB assays (48h) were conducted using selected concentrations within the same micromolar window, enabling consistent comparison between methods. In SRB, growth was determined using T0 and T1 measurements, and GI50 values were obtained by sigmoidal regression. Cisplatin and 5-fluorouracil were used as positive controls.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The complexes displayed clear metal-dependent antiproliferative profiles and cell line–specific sensitivity. Overall, HaCaT keratinocytes were largely preserved, with GI50 &gt; 100 µM for most tested complexes, supporting a favorable selectivity window relative to tumor models. Among the candidates, C5 was the most potent compound, showing GI50 = 0.3 µM in FaDu, while remaining non-cytotoxic to HaCaT within the tested range (GI50 &gt; 100 µM). In SCC-9, two compounds stood out: C4 (GI50 = 1.7 µM) and C7 (GI50 = 2.0 µM), both with GI50 &gt; 100 µM in HaCaT, indicating tumor-directed activity. C6 showed the most consistent tumor activity across models (GI50 = 23.6 µM in SCC-25; 7.8 µM in SCC-9; 7.3 µM in FaDu) while also maintaining GI50 &gt; 100 µM in HaCaT, suggesting an improved safety margin. In contrast, C2 and C3 were inactive (GI50 &gt; 100 µM) across the evaluated tumor lines. Reference drugs behaved as expected, with cisplatin showing high activity but measurable impact in HaCaT (GI50 = 7.4 µM) and 5-fluorouracil exhibiting moderate broad activity including HaCaT.&lt;/div&gt;&lt;/div&gt;&lt;","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 ","pages":"Article 106300"},"PeriodicalIF":1.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147449090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic insights into the antiproliferative effect of the redox-active iron chelator Dp44mT on multiple myeloma cell lines","authors":"Aarti Sharma ,&nbsp;Latha Pathangey ,&nbsp;Sinto Sebastian Chirackal ,&nbsp;Kiran K. Mangalaparthi ,&nbsp;Akhilesh Pandey ,&nbsp;Rafael Fonseca ,&nbsp;Sundararaman Swaminathan","doi":"10.1016/j.htct.2025.106233","DOIUrl":"10.1016/j.htct.2025.106233","url":null,"abstract":"<div><h3>Background</h3><div>Impaired iron metabolism has been linked to the pathogenesis of multiple myeloma. Redox active iron chelators have gained attention as potential anti-cancer agents as they target the high iron dependency of cancer cells. This study explored the potential mechanisms underlying the anti-multiple myeloma effect of the redox active iron chelator Dp44mT (Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone).</div></div><div><h3>Methods</h3><div>The effect of Dp44mT was tested on both immunomodulatory drug-sensitive and drug-resistant multiple myeloma cell lines using the MTT assay. Proteomic and phosphoproteomics characterization were utilized to explore the mechanisms of Dp44mT action on multiple myeloma cells. In addition, a real-time polymerase chain reaction assay was performed to examine the expressions of major iron metabolism genes. Reactive oxygen species, lipid peroxidation, mitochondrial membrane potential, and intracellular iron compartmentalization were measured using flow-cytometry.</div></div><div><h3>Results</h3><div>The high potency of Dp44mT in killing multiple myeloma cell lines was confirmed. Treatment with Dp44mT showed evidence of deregulated cellular iron metabolism, reactive oxygen species homeostasis, and mitochondrial membrane potential in multiple myeloma cell lines. As possible mechanistic pathways of Dp44mT, there was overrepresentation of the AMPK pathway, cell cycle, endoplasmic stress, and down regulation of <em>ACSL4</em> (<em>acyl-CoA synthetase long chain family member 4</em>).</div></div><div><h3>Conclusion</h3><div>This study suggests an in vitro, anti-multiple myeloma effect of Dp44mT that appears to be mediated by dysregulated iron metabolism, reactive oxygen species, and other biological pathways.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 1","pages":"Article 106233"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145829343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating comprehensive care in the management of sickle cell disease patients in Nigeria","authors":"Efobi Chilota Chibuife ,&nbsp;Nri-Ezedi Chisom Adaobi ,&nbsp;Chilaka Ugochinyere Jenny ,&nbsp;Okoye Helen Chioma ,&nbsp;Anigbogu Ikechukwu Okwudili ,&nbsp;Okwummuo Emeka Paul ,&nbsp;Ogundeji Sunday Peter ,&nbsp;Eze Onyinye Ezinne","doi":"10.1016/j.htct.2025.106091","DOIUrl":"10.1016/j.htct.2025.106091","url":null,"abstract":"<div><h3>Introduction</h3><div>Comprehensive sickle cell care is a holistic, multidisciplinary approach spanning from birth to adulthood. It includes newborn screening, routine investigations, medications, specific therapies and structured referrals. It is recognised since the 1972 US Sickle Cell Control Act and reinforced by the American Society of Haematology initiatives. This study evaluates the adoption of these strategies by physicians in Nigeria.</div></div><div><h3>Aim</h3><div>To examine the extent to which comprehensive care strategies are implemented in the management of sickle cell disease by adult and paediatric haematologists in Nigeria.</div></div><div><h3>Methodology</h3><div>This cross-sectional study was conducted from September to November 2022 across six tertiary hospitals. An adapted and pretested primary care assessment tool was used to collect data on physician demographics and strategic components of comprehensive care. Descriptive statistics and chi-square tests were used to analyse the data.</div></div><div><h3>Results</h3><div>A total of 157 doctors participated with most working in tertiary hospitals. Folic acid and proguanil hydrochloride were the most prescribed drugs; fewer than 50% used hydroxyurea. A complete blood count was the most requested investigation with 58% routinely scheduling investigations. Adult haematologists ordered more echocardiograms and paediatric haematologists requested more transcranial Dopplers. Adult haematologists referred more across specialities (p-value = 0.0001). All participants routinely counselled patients on clinic attendance, medication adherence and healthy lifestyle practices.</div></div><div><h3>Conclusion</h3><div>Key components of comprehensive care are practised at varying levels by health professionals in Nigeria, mainly in urban/tertiary hospitals. To strengthen nationwide delivery of care, health policies should prioritise equitable workforce distribution and integration of additional services, like neonatal screening and emerging therapies.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 1","pages":"Article 106091"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145425669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphoma-associated hemophagocytic lymphohistiocytosis","authors":"Thomás de Souza Patto Marcondes ,&nbsp;Carlos Sérgio Chiattone ,&nbsp;Rafael Dezen Gaiolla","doi":"10.1016/j.htct.2025.106087","DOIUrl":"10.1016/j.htct.2025.106087","url":null,"abstract":"<div><div>Hemophagocytic lymphohistiocytosis is a severe, rare condition characterized by excessive immune activation, leading to significant morbidity and mortality. Lymphoma is the most common trigger for malignancy-related hemophagocytic lymphohistiocytosis in adults, with large B-cell non-Hodgkin, T- and NK-cell lymphomas being the most diagnosed. Hodgkin lymphoma is less frequently observed. Lymphoma-associated hemophagocytic lymphohistiocytosis poses diagnostic and therapeutic challenges due to its complex pathogenesis and heterogeneous presentation. Treatment aims to control the overactive immune system, identify and treat modifying factors, optimize clinical support, and treat the underlying lymphoma. Early etoposide (Etoposide) combined with dexamethasone for immunomodulation results in rapid control of hyperinflammation and clinical improvement. It has increasingly been adopted as a standard initial approach followed by lymphoma-specific treatment. However, the outcomes for patients with lymphoma-associated hemophagocytic lymphohistiocytosis remain poor, especially for patients with T- and NK-cell lymphomas. In relapsed or refractory cases, emerging therapies have been explored, with ruxolitinib showing the most promising results. This paper reviews current understanding of the epidemiology, pathogenesis, clinical features, diagnosis, and treatment of lymphoma-associated hemophagocytic lymphohistiocytosis in adults and proposes an appropriate treatment protocol based on the most recent data from the literature.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 1","pages":"Article 106087"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145558847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obstetrical use of intravenous immunoglobulin: A single-centre retrospective study","authors":"Roy Khalife ,&nbsp;Bonnie Niu ,&nbsp;Iris Perelman ,&nbsp;Darine El-Chaâr ,&nbsp;Dean Fergusson ,&nbsp;Alan Karovitch ,&nbsp;Johnathan Mack ,&nbsp;Melanie Tokessy ,&nbsp;Kathryn E. Webert ,&nbsp;Alan Tinmouth","doi":"10.1016/j.htct.2025.106225","DOIUrl":"10.1016/j.htct.2025.106225","url":null,"abstract":"<div><h3>Introduction</h3><div>Intravenous immunoglobulin is widely used for various conditions but faces challenges such as limited supply, high cost, and substantial off-label use. Obstetrical intravenous immunoglobulin use remains underexplored, despite its relevance to maternal and neonatal care and resource management.</div></div><div><h3>Methods</h3><div>This single-center retrospective cohort study examined intravenous immunoglobulin administration in 136 pregnancies (122 patients) from 2007–2020, focusing on adherence to Health Canada licensed indications and Ontario Immunoglobulin Utilization Management Guidelines.</div></div><div><h3>Results</h3><div>Maternal thrombocytopenia (56.6 %) and treatment for fetal/neonatal alloimmune thrombocytopenia (16.2 %) were the most common indications, accounting for 16.9 % and 64.3 % of total intravenous immunoglobulin volume, respectively. Intravenous immunoglobulin use represented 1.6 % of the center's total consumption during the study period, with notable non-adherence to guidelines in 38.2 % (Health Canada) and 17.6 % (provincial guidelines) of pregnancies.</div></div><div><h3>Conclusion</h3><div>Findings highlight the need for optimized intravenous immunoglobulin use in obstetrics and future research to ensure safety, efficacy, and evidence-based guidance in clinical practice and policy.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 1","pages":"Article 106225"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145690338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First report of perioperative iptacopan interruption in paroxysmal nocturnal hemoglobinuria without breakthrough hemolysis","authors":"Katsuhiro Tokuda ,&nbsp;Tatsuki Morioka ,&nbsp;Shoya Arai ,&nbsp;Takuji Matsuo ,&nbsp;Kensuke Matsumoto ,&nbsp;Ryosuke Shirasaki ,&nbsp;Jun Ooi ,&nbsp;Haruko Tashiro","doi":"10.1016/j.htct.2025.106235","DOIUrl":"10.1016/j.htct.2025.106235","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 1","pages":"Article 106235"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145746859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety analysis of the use of ibrutinib associated with rituximab for the first-line treatment of patients with chronic lymphocytic leukaemia","authors":"Aline do Nascimento ,&nbsp;Daniel da Silva Pereira Curado ,&nbsp;Thais Montezuma ,&nbsp;Wallace Breno Barbosa ,&nbsp;Juliana Machado-Rugolo ,&nbsp;Mariana Millan Fachi","doi":"10.1016/j.htct.2025.106234","DOIUrl":"10.1016/j.htct.2025.106234","url":null,"abstract":"<div><h3>Introduction</h3><div>Chronic lymphocytic leukaemia, a common blood cancer in adults, particularly affects the elderly and is marked by the accumulation of B lymphocytes. While therapeutic options have expanded, the fludarabine, cyclophosphamide, and rituximab (FCR) regimen remains the standard first-line treatment for fit patients in the Brazilian public health system.</div></div><div><h3>Aim</h3><div>This systematic review aimed to assess the efficacy and safety of ibrutinib plus rituximab (IR) as a first-line therapy for chronic lymphocytic leukaemia.</div></div><div><h3>Methods</h3><div>Following PRISMA guidelines and registered in PROSPERO (CRD42023494868), searches were conducted in multiple databases in December 2023 to identify relevant randomized controlled trials comparing the IR and FCR regimens. Eligible studies reported at least one of the following outcomes: progression-free survival, overall survival, severe adverse events, or quality of life.</div></div><div><h3>Results</h3><div>Two double-blind randomized controlled trials (FLAIR and E1912) totalling 1300 patients met inclusion criteria. Meta-analysis showed that the IR regimen significantly improved progression-free survival compared to the FCR regimen (Hazard ratio: 0.41; 95% CI: 0.31–0.53) with moderate certainty of evidence. However, overall survival did not differ substantially (Hazard ratio: 0.71; 95% CI: 0.33–1.49), and the certainty of the evidence was very low. Quality of life data were unavailable. Due to variations in follow-up, results for severe adverse events were not pooled and the individual studies reported results with low certainty of evidence. The global risk of bias was rated as there was some concern due to the lack of concealed allocation in all outcomes.</div></div><div><h3>Conclusion</h3><div>The IR regimen demonstrated superior progression-free survival and comparable safety to the FCR regimen suggesting it is an effective and safe option for first-line treatment of chronic lymphocytic leukaemia.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 1","pages":"Article 106234"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145770499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}